Endocrine Abstracts

Objective: investigate the assosiation between presence of sarcopenia and type 2 diabetes mellitus (T2DM).

Methods: The study included 138 women over 60 years old (Me 72[67;78] years) (76 patients with T2DM). Patients were examined with evaluation of muscle mass, muscle strength and muscle function. Muscle strength was measured with carpal dynamometry, muscle function was evaluated with short physical performance battery tests. Skeletal muscle mass index (SMMI) was evaluated with bioimpedance testing. Sarcopenia was defined as a SMMI ≤6.75 kg/m². Peripheral neuropathy was studied with calculation of NIS-LL scale (max points=96). Patients with T2DM were divided into 2 groups: with sarcopenia (S+, n=29) and without sarcopenia (S−, n=47). We did not find any significant difference between age and diabetes duration in S+ and S- groups. Multivariable logistic regression model were adjusted for age.

Results: Sarcopenia was observed in 29 patients (38%). The frequency of HbA1c level more then 8% were 72% in S+ group and 49% in group S− (P=0.041). Glower filtration rate was lower in S+ group than S− group (60[49;71.5] vs 67[59.5;75.5]ml/min, P=0.043). S+ group less frequently received metformin (P=0.011) and insulin (P=0.044). Diabetic neuropathy was more severe in S+ group than in S− group (NIS-LL: 12[7;17] vs 6 [4.8], P<0.001). Frequency of falls and fractures was noted more often in S+ group than in S- group (66% vs 36%, P=0.013, 36% vs 13%, P=0.003). The univariate logistic regression analysis revealed the associations of presence of sarcopenia in T2DM patients with HbA1c over 8% (OR-2.74; 95%CI[1.01–7.4], P=0.047), history of falls≥2 (OR-3.35; 95%CI[1.27–8.84], P=0.014) and NISLL more than 11 points (OR-23.89; 95%CI[6.56–86.94], P<0.001). The multivariable logistic regression analysis revealed the associations of presence of sarcopenia in T2DM patients with NISLL more then 11 points (OR-22.14; 95%CI[3.68–133.30], P=0.001).

Conclusions: Sarcopenia evaluated with biompedance technique with calculation SMI≤6.75 kg/m² and with or without decrease of muscle function or strength associated with presence of peripheral sensomotor neuropathy, poor glycemic control, lack of treatment with metformin.